MarketCapExport financials
Akebia Therapeutics (AKBA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Akebia Therapeutics Balance Sheet 2025-2011 | AKBA
Brief balance sheet overview of Akebia Therapeutics
This overview follows the five latest available annual observations between 2021 and 2025.
Assets fell from $529.3 million to $376.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Assets and liabilities changed at similar rates, -28.9% and -24.5%. The funding mix did not shift sharply.
Equity covers only 8.7% of assets versus 14% initially. The loss-absorbing cushion is limited.
The period ended with net cash: net debt stood at -$133 million. This supports financial flexibility.
Cash equals 49.1% of the balance sheet, compared with 28.3% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$1.7 billion. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Akebia Therapeutics has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-133 M | -7.78 M | -21.3 M | -51.6 M | -111 M | -127 M | -39.1 M | -89.6 M | -70.2 M | -187 M | -49.8 M | -32.8 M | -21.2 M | -1.64 M | - |
Long Term Debt |
48.2 M | 38.7 M | 17.2 M | 34.1 M | 33.7 M | 96.4 M | 75.8 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.55 M | 5.4 M | 4.49 M | 4.74 M | 4.8 M | 5.29 M | 4.99 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 168 M | 94.9 M | 101 M | 118 M | 74 K | 32 K | 8 K | - | - |
Total Current Liabilities |
163 M | 80.9 M | 99.9 M | 130 M | 261 M | 187 M | 208 M | 266 M | 144 M | 114 M | 11.9 M | 6.88 M | - | - | - |
Total Liabilities |
344 M | 270 M | 272 M | 351 M | 455 M | 397 M | 376 M | 361 M | 245 M | 232 M | 11.9 M | 6.92 M | 3.91 M | 4.92 M | - |
Deferred Revenue |
2.68 M | - | - | 3.74 M | 20.9 M | 15.2 M | 39.8 M | 57 M | 84.9 M | 82 M | - | - | - | - | - |
Retained Earnings |
-1.68 B | -1.68 B | -1.61 B | -1.56 B | -1.46 B | -1.18 B | -794 M | -514 M | -374 M | -297 M | -161 M | -101 M | -63.7 M | -59.6 M | - |
Total Assets |
377 M | 221 M | 242 M | 356 M | 529 M | 644 M | 771 M | 997 M | 364 M | 300 M | 143 M | 111 M | 34.7 M | 2.24 M | - |
Cash and Cash Equivalents |
185 M | 51.9 M | 42.9 M | 90.5 M | 150 M | 229 M | 147 M | 105 M | 70.2 M | 187 M | 49.8 M | 32.8 M | 21.2 M | 1.64 M | - |
Book Value |
32.6 M | -49.2 M | -30.6 M | 5.23 M | 74 M | 248 M | 395 M | 636 M | 119 M | 68.1 M | 131 M | 104 M | 30.8 M | -2.68 M | - |
Total Shareholders Equity |
32.6 M | -49.2 M | -30.6 M | 5.23 M | 74 M | 244 M | 395 M | 636 M | 123 M | 68.1 M | 131 M | 104 M | -127 M | -59.6 M | - |
All numbers in USD currency
Quarterly Balance Sheet Akebia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
24.8 M | 36.4 M | 47.6 M | 47.1 M | 46.5 M | 38.7 M | 38.4 M | 38 M | - | 17.2 M | 34.6 M | 18.5 M | 26.3 M | 34.1 M | 65.9 M | - | 32.6 M | 33.7 M | 97.2 M | 96.9 M | 96.6 M | 96.4 M | 96.4 M | 96.4 M | 96.4 M | 75.8 M | 75.8 M | 75.8 M | 75.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
325 M | 335 M | 323 M | 316 M | 286 M | 270 M | 258 M | 254 M | - | 272 M | 274 M | 281 M | 291 M | 351 M | 422 M | 471 M | 509 M | 449 M | 465 M | 437 M | 415 M | 397 M | 397 M | 397 M | 397 M | 376 M | 376 M | 376 M | 376 M | 361 M | 361 M | 361 M | 361 M | 242 M | 242 M | 242 M | 242 M | 232 M | 232 M | 232 M | 232 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 6.92 M | 6.92 M | 6.92 M | 6.92 M | 3.91 M | 3.91 M | 3.91 M | 3.91 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
6.17 M | 4.5 M | 3.88 M | 5.53 M | 1.24 M | - | - | 43.3 M | - | - | - | - | - | 3.74 M | 1.26 M | - | 10.4 M | 20.9 M | 15.7 M | 11.9 M | 18.3 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M | 57 M | 57 M | 78.6 M | 78.6 M | 81.7 M | 121 M | 142 M | 81.7 M | 82 M | 82 M | 82 M | 82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.7 B | -1.69 B | -1.67 B | -1.67 B | -1.67 B | -1.68 B | -1.66 B | -1.64 B | - | -1.61 B | -1.61 B | -1.6 B | -1.58 B | -1.56 B | -1.55 B | -1.5 B | -1.52 B | -1.46 B | -1.39 B | -1.33 B | -1.25 B | -1.18 B | -1.18 B | -1.18 B | -1.18 B | -794 M | -794 M | -794 M | -794 M | -514 M | -514 M | -514 M | -514 M | -371 M | -371 M | -371 M | -371 M | -297 M | -297 M | -297 M | -297 M | -161 M | -161 M | -161 M | -161 M | -101 M | -101 M | -101 M | -101 M | -127 M | -127 M | -127 M | - | - | - | - | - | - | - | - | - |
Total Assets |
350 M | 363 M | 364 M | 346 M | 310 M | 221 M | 207 M | 220 M | - | 242 M | 235 M | 254 M | 277 M | 356 M | 436 M | 530 M | 535 M | 526 M | 602 M | 612 M | 629 M | 644 M | 644 M | 644 M | 644 M | 771 M | 771 M | 771 M | 771 M | 997 M | 997 M | 997 M | 997 M | 364 M | 364 M | 364 M | 364 M | 300 M | 300 M | 300 M | 300 M | 143 M | 143 M | 143 M | 143 M | 111 M | 111 M | 111 M | 111 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
156 M | 163 M | 166 M | 137 M | 113 M | 51.9 M | 35.7 M | 41.2 M | 43.6 M | 42.9 M | 48.2 M | 55.3 M | 57 M | 90.5 M | 148 M | 147 M | 178 M | 150 M | 209 M | 247 M | 253 M | 229 M | 229 M | 229 M | 229 M | 147 M | 147 M | 147 M | 147 M | 105 M | 105 M | 105 M | 105 M | 70.2 M | 70.2 M | 70.2 M | 70.2 M | 187 M | 187 M | 187 M | 187 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 1.64 M | - | - | - | 5.01 M | - | - | - |
Book Value |
25 M | 27.4 M | 41.6 M | 29.2 M | 24.6 M | -49.2 M | -50.4 M | -33.8 M | - | -30.6 M | -39.4 M | -26.8 M | -14.4 M | 5.23 M | 13.9 M | 58.9 M | 26.1 M | 76.5 M | 137 M | 175 M | 214 M | 248 M | 248 M | 248 M | 248 M | 395 M | 395 M | 395 M | 395 M | 636 M | 636 M | 636 M | 636 M | 123 M | 123 M | 123 M | 123 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | 131 M | 131 M | 131 M | 131 M | 104 M | 104 M | 104 M | 104 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
25 M | 27.4 M | 41.6 M | 29.2 M | 24.6 M | -49.2 M | -50.4 M | -33.8 M | -27.3 M | -30.6 M | -39.4 M | -26.8 M | -14.4 M | 5.23 M | 8.26 M | 58.9 M | 26.1 M | 76.5 M | 137 M | 175 M | 214 M | 248 M | 248 M | 248 M | 248 M | 395 M | 395 M | 395 M | 395 M | 636 M | 636 M | 636 M | 636 M | 123 M | 123 M | 123 M | 123 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | 131 M | 131 M | 131 M | 131 M | 104 M | 104 M | 104 M | 104 M | -127 M | -127 M | -127 M | -127 M | -59.6 M | - | - | - | -48.2 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Akebia Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Ionis Pharmaceuticals
IONS
|
$ 43.5 | 0.62 % | $ 6.96 B |  USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
$ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
$ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
$ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
$ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
$ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
$ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
$ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
$ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
$ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
$ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
$ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
$ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
$ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
$ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
$ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
$ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
$ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
$ 4.2 | 0.24 % | $ 651 M | USA |
 |
Annovis Bio
ANVS
|
$ 1.2 | 1.69 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.68 | 0.16 % | $ 4.45 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.8 | 2.27 % | $ 568 K | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.57 | 0.44 % | $ 489 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 14.66 | 12.51 % | $ 401 M | Israel |
 |
Ardelyx
ARDX
|
$ 3.39 | 1.5 % | $ 817 M | USA |
 |
argenx SE
ARGX
|
$ 912.87 | 1.28 % | $ 56 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.66 | 3.98 % | $ 133 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 25.15 | 0.04 % | $ 3.2 B | USA |